PTCT Latest Press Releases

-- October 15, 2026 --

PTC Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, Oct. 29, 2026 PRNewswire 8:01 AM

-- September 25, 2026 --

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PRNewswire 4:30 PM

-- September 21, 2026 --

PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy PRNewswire 4:30 PM

-- August 27, 2026 --

PTC Therapeutics to Participate in Upcoming Investor Conferences PRNewswire 8:01 AM

-- August 24, 2026 --

PTC Therapeutics Announces New Sephience (sepiapterin) Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as well as Consistent Favorable Safety Profile PRNewswire 8:00 AM

-- August 12, 2026 --

PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program PRNewswire 4:02 PM

-- July 30, 2026 --

PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results PRNewswire 4:01 PM

-- July 23, 2026 --

Hamilton Lane Board Elects Michael Schmertzler as New Independent Director PRNewswire 7:39 AM

-- July 16, 2026 --

PTC Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, July 30, 2026 PRNewswire 8:00 AM

-- June 17, 2026 --

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PRNewswire 4:31 PM

-- June 15, 2026 --

PTC Therapeutics Announces Pricing of Convertible Notes Offering to Refinance 2026 Convertible Notes PRNewswire 11:15 PM

PTC Therapeutics Announces Proposed Convertible Notes Offering to Refinance 2026 Convertible Notes PRNewswire 7:01 AM

Market Data Delayed 15 Minutes